Jpmorgan Chase & CO Savara Inc Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Savara Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 57,070 shares of SVRA stock, worth $211,159. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,070

Previous 166,992 65.82%

Holding current value

$211,159

Previous $831,000 72.44%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$3.66 - $5.34 $402,314 - $586,983	-109,922 Reduced 65.82%	57,070 $229,000
Q1 2024 May 10, 2024	BUY	$4.19 - $5.59 $337,919 - $450,827	80,649 Added 93.41%	166,992 $831,000
Q4 2023 Feb 12, 2024	BUY	$3.18 - $4.9 $78,730 - $121,314	24,758 Added 40.2%	86,343 $405,000
Q3 2023 Nov 14, 2023	BUY	$2.97 - $3.88 $6,507 - $8,501	2,191 Added 3.69%	61,585 $232,000
Q2 2023 Aug 11, 2023	BUY	$1.69 - $3.24 $451 - $865	267 Added 0.45%	59,394 $189,000
Q1 2023 May 11, 2023	BUY	$1.6 - $2.82 $55,030 - $96,991	34,394 Added 139.06%	59,127 $115,000
Q4 2022 Feb 13, 2023	BUY	$1.11 - $1.64 $3,573 - $5,279	3,219 Added 14.96%	24,733 $38,000
Q3 2022 Nov 14, 2022	SELL	$1.36 - $1.88 $1,940 - $2,682	-1,427 Reduced 6.22%	21,514 $33,000
Q2 2022 Aug 11, 2022	SELL	$1.1 - $1.58 $12,086 - $17,361	-10,988 Reduced 32.39%	22,941 $34,000
Q1 2022 May 11, 2022	SELL	$1.05 - $1.36 $132,537 - $171,667	-126,226 Reduced 78.81%	33,929 $44,000
Q4 2021 Feb 10, 2022	BUY	$1.04 - $1.34 $109,466 - $141,043	105,256 Added 191.73%	160,155 $198,000
Q3 2021 Nov 12, 2021	BUY	$1.18 - $1.64 $64,780 - $90,034	54,899 New	54,899 $75,000

Others Institutions Holding SVRA

# of Institutions

144

Shares Held

147M

Call Options Held

242K

Put Options Held

797K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $422M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Savara Inc Transaction History